Profile data is unavailable for this security.
About the company
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
- Revenue in CAD (TTM)0.00
- Net income in CAD-26.68m
- Incorporated2015
- Employees16.00
- LocationMedicenna Therapeutics Corp2 Bloor St W., 7Th FloorTORONTO M4W 3E2CanadaCAN
- Phone+1 (416) 648-5555
- Fax+1 (416) 648-5555
- Websitehttps://www.medicenna.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZYUS Life Sciences Corp | 428.00k | -36.83m | 62.46m | 2.00 | -- | 3.83 | -- | 145.94 | -0.5247 | -0.5247 | 0.0061 | 0.2192 | 0.0074 | 0.075 | 0.5757 | -- | -63.34 | -57.88 | -88.37 | -71.19 | 46.50 | -16.16 | -8,604.67 | -10,367.37 | 0.1593 | -35.94 | 0.3955 | -- | 17.79 | 213.99 | -72.73 | -- | -- | -- |
| MustGrow Biologics Corp | 4.71m | -423.96k | 91.37m | 0.00 | -- | 25.36 | -- | 19.39 | -0.0078 | -0.0078 | 0.0927 | 0.0726 | 0.9337 | -- | 32.60 | -- | -8.40 | -50.41 | -11.41 | -59.28 | -- | -- | -9.00 | -298.73 | 4.84 | -- | 0.1215 | -- | 72,619.13 | 372.54 | 87.84 | -- | -- | -- |
| Satellos Bioscience Inc | 0.00 | -28.53m | 91.84m | 12.00 | -- | 4.46 | -- | -- | -0.2528 | -0.2528 | 0.00 | 0.1816 | 0.00 | -- | -- | 0.00 | -78.28 | -107.22 | -85.23 | -136.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.33 | -- | 459.46 | -- |
| Oncolytics Biotech Inc | 0.00 | -27.64m | 105.54m | 29.00 | -- | 11.66 | -- | -- | -0.3644 | -0.3644 | 0.00 | 0.1175 | 0.00 | -- | -- | -- | -78.58 | -81.99 | -104.96 | -97.25 | -- | -- | -- | -- | -- | -- | 0.1051 | -- | -- | -- | -11.75 | -- | -40.52 | -- |
| Medicenna Therapeutics Corp | 0.00 | -26.68m | 113.88m | 16.00 | -- | 5.72 | -- | -- | -0.3747 | -0.3747 | 0.00 | 0.2603 | 0.00 | -- | -- | 0.00 | -87.95 | -54.93 | -98.62 | -60.91 | -- | -- | -- | -- | -- | -2.20 | 0.0087 | -- | -- | -- | -153.44 | -- | -- | -- |
| Zentek Ltd | 39.36k | -10.74m | 166.50m | 25.00 | -- | 8.96 | -- | 4,230.28 | -0.1062 | -0.1062 | 0.0004 | 0.1785 | 0.0016 | 0.2262 | 0.1059 | 1,574.40 | -44.08 | -47.65 | -48.37 | -51.12 | -1,038.69 | -- | -27,288.92 | -13,980.33 | 1.63 | -140.86 | 0.0474 | -- | -59.07 | -- | 18.80 | -- | -19.38 | -- |
| Eupraxia Pharmaceuticals Inc | 0.00 | -39.52m | 168.49m | 29.00 | -- | 12.67 | -- | -- | -1.38 | -1.38 | 0.00 | 0.3734 | 0.00 | -- | -- | 0.00 | -162.00 | -127.84 | -261.49 | -935.99 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -52.63 | -- | -7.69 | -- |
